Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Stege

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Urologia Internationalis|January 1, 1987
Serum prolactin assays have no prognostic value in treatment of prostatic cancer by orchidectomy or estrogensR Stege, K Carlström, A Eriksson, et al.
The Prostate|May 15, 1997
Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinomaK Carlström, R Stege, P Henriksson, et al.
The Prostate|May 1, 1996
Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patientsR Stege, P O Gunnarsson, C J Johansson, et al.
Lancet (London, England)|November 18, 1989
Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostateP Henriksson, M Eriksson, S Ericsson, et al.
Der Urologe. Ausg. A|September 1, 1995
[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status]R Stege, K Carlström, P O Hedlund, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1996
Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in malesL Berglund, K Carlström, R Stege, et al.
The Prostate|January 1, 1989
A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomyK Carlström, L Collste, A Eriksson, et al.
The Prostate|January 1, 1989
Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimensR Stege, K Carlström, L Collste, et al.
The Prostate|January 1, 1989
Estrogen therapy and liver function--metabolic effects of oral and parenteral administrationB von Schoultz, K Carlström, L Collste, et al.
British Journal of Urology|March 1, 1997
Prostate-specific antigen in tissue from fine-needle aspiration biopsiesA Pousette, K Carlström, B Tribukait, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Urologia Internationalis|January 1, 1987
Serum prolactin assays have no prognostic value in treatment of prostatic cancer by orchidectomy or estrogensR Stege, K Carlström, A Eriksson, et al.
The Prostate|May 15, 1997
Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinomaK Carlström, R Stege, P Henriksson, et al.
The Prostate|May 1, 1996
Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patientsR Stege, P O Gunnarsson, C J Johansson, et al.
Lancet (London, England)|November 18, 1989
Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostateP Henriksson, M Eriksson, S Ericsson, et al.
Der Urologe. Ausg. A|September 1, 1995
[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status]R Stege, K Carlström, P O Hedlund, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1996
Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in malesL Berglund, K Carlström, R Stege, et al.
The Prostate|January 1, 1989
A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomyK Carlström, L Collste, A Eriksson, et al.
The Prostate|January 1, 1989
Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimensR Stege, K Carlström, L Collste, et al.
The Prostate|January 1, 1989
Estrogen therapy and liver function--metabolic effects of oral and parenteral administrationB von Schoultz, K Carlström, L Collste, et al.
British Journal of Urology|March 1, 1997
Prostate-specific antigen in tissue from fine-needle aspiration biopsiesA Pousette, K Carlström, B Tribukait, et al.
Pageof 5